Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion type Assertion NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_head.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion description "[Five-year risk of progression or recurrence was doubled for patients with ALK-positive compared with ALK-negative tumors; ALK-positive tumors also appeared to be associated with a higher risk of brain and liver metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_provenance.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion evidence source_evidence_literature NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_provenance.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion SIO_000772 22134072 NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_provenance.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion wasDerivedFrom befree-20140225 NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_provenance.
- NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_assertion wasGeneratedBy ECO_0000203 NP615550.RA4HDNY2RaEJZIL8cxQLC_RcjGfGke0KMF3ae0iXIE758130_provenance.